Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 2 No. 1 (1996)

New Perspectives in the Pharmacologic Treatment of Primary Open-Angle Glaucoma: Pathogenesis and Patient Factors

  • Kevin A. Waschke, B.Sc.
November 9, 2020




  1. Albert DM. Principles and Practice of Ophthalmology. Philadelphia, PA: WB Saunders and Co.; 1994: 1342-1345, 1569-1577.
  2. Spencer WH. Ophthalmic Pathology. New York: WB Saunders and Co.; 1986: 487-547.
  3. Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis, MO: CV Mosby and Co.; 1989: 199-218, 827.
  4. Johnson DH, Brubaker RF. Glaucoma: An Overview. Mayo Clinic Proceedings 6(1): 59-67; 1986.
  5. Klein BE, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. Ophthalmology 101(7): 1173-1177; 1994.
  6. Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma. The Barbados Eye Study, Archives of Ophthalmology 113(7): 918-924; 1995.
  7. Carter CJ, Brooks DE, Doyle DL, Drance SM. Investigations into a vascular etiology for low tension glaucoma. Ophthalmology 97(1): 49-55; 1990.
  8. Drance SM, et al. Studies of factors involved in the production of low tension glaucoma. Archives of Ophthalmology 89(6): 457-465; 1973.
  9. Drance SM, Douglas GR, Wijsman K, et al. Response of blood flow to warm and cold in normal and low tension glaucoma patients. American Journal of Ophthalmology 105(1): 35-39; 1988.
  10. Gasser P. Ocular vasospasm: a risk factor in the pathogenesis of low-tension glaucoma. International Ophthalmology 13(4): 282-290; 1989.
  11. Phelps CD, Corbett JJ. Migraine and low-tension glaucoma: a case-control study. Inverstigational Ophthalmology & Visual Science 26(8): 254-263, 1105-1108; 1985.
  12. Friedlaender M, Bartlett J. Brave new world of ophthalmic drugs. Eyecare Technology Magazine; 1995.
  13. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group. American Journal of Ophthalmology 120(1): 10-22; 1995.
  14. Migdal C. What is the appropriate treatment for patients with primary open-angle glaucoma: medicine, laser or primary surgery? Ophthalmic Surgery 26(2): 108-110; 1995.
  15. Sherwood MB, Migdal CS, Hitchings RA, et al. Initial treatment of glaucoma: surgery or medications. Survey of Ophthalmology 37(4): 293-305; 1993.
  16. Bartlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology. 2nd ed. Boston: Butterworths; 1989: 245-265.
  17. Apple DJ, Naumann GOH. Pathology of the Eye. New York: Springer-Verlag; 1986: 771-790.
  18. Becker B. The decline of aqueous secretion and outflow with age. American Journal of Ophthalmology 46: 731; 1958.
  19. Lee WR. Doyne Lecture. The pathology of the outflow system in primary and secondary glaucoma. Eye 9(1): 1-23; 1995.
  20. Schappert-Kimmijser J. A five-year follow-up of subjects with intraocular pressure of 22-30 mm Hg
  21. without anomalies of optic nerve and visual field typical for glaucoma at first investigation. Ophthalmologica 162(4): 289-295; 1971.
  22. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the collaborative glaucoma study: summary report of the risk factors for glaucomatous visual-field defects. Archives of Ophthalmology 98(12): 2163-2171; 1980.
  23. Fechter RD, Weinreb RN. Mechanisms of optic nerve damage in primary open-angle glaucoma. Survey of Ophthalmology 39(1): 23-42; 1994.
  24. Weinreb RN. Why study the ocular microcirculation in glaucoma. Journal of Glaucoma 1: 145-147; 1992.
  25. Drance SM. Bowman Lecture. Glaucoma: Changing concepts. Eye 6(2): 337-345; 1992.
  26. Jay JL. Rational choice of therapy in primary open-angle glaucoma. Eye 6(3): 243-247; 1992.
  27. Brown MM, Brown GC, Spaeth GL. Improper topical self-administration of ocular medication among patients with glaucoma. Canadian Journal of Ophthalmology 19(1): 2-5; 1984.
  28. Novack GD, David R, Lee PF, et al. Effect of changing medication regimens in glaucoma patients. Ophthalmologica 196(1): 23-28; 1988.
  29. Frishman WH, Fuksbrumer MS, Tannenbaum M. Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. Journal of Clinical Pharmacology 34(8): 795-803; 1994.
  30. Zimmerman TJ, Kooner KS, editors. Ophtalmology Clinics of North America. New York, NY: WB Saunders and Co., 1989, 2(1): 77-87.
  31. Trope GE, Menon IA, Liu GS, et al. Ocular timolol levels after drug withdrawal: an experimental model. Canadian Journal of Ophthalmology 29(5): 217-219; 1994.
  32. Neufeld AH, Drance SM, VanBuskirk, eds. Pharmacology of Glaucoma. Williams and Wilkins; 1992, 66-67, 293, 302-325.
  33. Schoene RB, Martin TR, Charan NB, French CL. Timolol-induced bronchospasm in asthmatic bronchitis. Journal of the American Medical Association 245(14): 1460-1461; 1981.
  34. O'Donoghue E. Beta-blockers and the elderly with glaucoma: are we adding insult to injury? British Journal of Ophthalmology 79(9): 794-796; 1995.
  35. Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management: clinical pharmacological aspects. Drugs & Aging 2(3): 208-221; 1992.
  36. Axelsson U, Holmberg A. The frequency of cataract after miotic therapy. Acta Ophthalmologica 44(3): 421-429; 1966.
  37. Hurvitz LM, Kaufman PL, Robin AL, et al. New developments in the drug treatment of glaucoma. Drugs 41(4): 514-532; 1991.
  38. Chiou GC. Treatment of open-angle glaucoma and iscemic retinopathy with dopamine antagonists. Journal of Ocular Pharmacology 10(1): 371-377; 1994.
  39. Crick RP, Newson RB, Shipley MJ, et al. The progress of the visual field in chronic simple glaucoma and ocular hypertension treated topically with pilocarpine or with timolol. Eye 4(4): 563-571; 1990.
  40. Hong SJ, Chiou GC. Effects of dopamine agonists and antagonists on pulsatile blood flow of ocular hypertensive rabbits. Journal or Ocular Pharmacology 9(2): 117-124; 1993.
  41. Chiou GC, Chen YJ. Effects of dopamine agonist, bromocriptine, and some dopamine antagonists on ocular blood flow. Journal of Ocular Pharmacology 8(4): 285-294; 1992.
  42. Netland PA, Chaturvedi N, Dreyer EB. Calcium-channel blockers in the management of low-tension and open-angle glaucoma. American Journal of Ophthalmology 115(5): 608-613; 1993.
  43. Gaspar AZ, Flammer J, Hendrickson P. Influence of nifedipine on the visual fields of patients with optic-nerve-head diseases. European Journal of Ophthalmology 4(1): 24-28; 1994.
  44. Schulzer M, Drance SM, Carter CJ, et al. Biostatistical evidence for two distinct chronic open-angle glaucoma populations. British Journal of Ophthalmology 74(4): 196-200; 1990.
  45. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. British Journal of Ophthalmology 79(1): 12-16; 1995.
  46. Bodor N. Designing safer ophthalmic drugs by soft drug approaches. Journal of Ocular Pharmacology 10(1): 3-15; 1994.


Download data is not yet available.